Environmental

DHR’s life-science tools portfolio supports lower direct environmental intensity than many industrial peers, because manufacturing and laboratory operations are less emissions-heavy than heavy equipment sectors.

R&D spending at 6.5% of revenue suggests a technology-led product mix, which can improve resource efficiency over time versus peers with more capital-intensive, energy-intensive production models.

The company still faces material Scope 3 and supply-chain footprint exposure, but this is broadly comparable to diversified healthcare-equipment peers rather than a clear structural disadvantage.

No major environmental controversy is evident in the provided data, so DHR appears better positioned than peers with higher regulatory exposure to hazardous materials or large-scale industrial emissions.

Social

DHR’s healthcare and laboratory end markets are socially supportive, because its products generally contribute to diagnostics, research, and patient-care workflows versus peers in lower-impact sectors.

R&D intensity of 6.5% of revenue indicates sustained product innovation, which can strengthen customer safety and usability outcomes relative to peers with weaker development investment.

Stock-based compensation at 1.5% of revenue suggests moderate dilution pressure, which is not a major social concern and appears manageable versus peers with heavier equity-based pay.

The main social risk is product quality and compliance across regulated end markets, but this is an industry-wide issue and not a clear relative weakness in the available data.

Governance

Debt-to-equity of 0.35 indicates a conservative balance-sheet posture, which typically supports governance discipline versus peers that rely more heavily on leverage.

Net debt to EBITDA of 3.45x suggests meaningfully higher financial leverage than previously indicated, increasing pressure for disciplined capital allocation compared with more conservatively financed peers.

Stock-based compensation at 1.5% of revenue is relatively contained, which supports alignment and limits compensation-related governance concerns versus peers with richer equity awards.

The available metrics do not indicate severe governance red flags, although a fuller assessment would still require board independence, audit, and controversy disclosures from filings.

Overall Score

DHR screens as a strong ESG performer versus peers, led by disciplined leverage, moderate compensation intensity, and a healthcare-oriented business mix with manageable environmental exposure.

Score Driver: Conservative Leverage And Generally Disciplined Capital Allocation Relative To Peers.